FDA approval of low dose RA drug Olumiant viewed by analyst

19 June 2018

The recent, and long-awaited, US approval of a low-dose rheumatoid arthritis drug will provide a competitive edge in market sector for the drug’s developers, Eli Lilly (NYSE: LLY) and partner Incyte (Nasdaq: INCY).

The approval of Olumiant (baricitinib) 2mg tablets as a once-daily oral medication for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) by the US Food and Drug Administration, will give Eli Lilly and Incyte Corp a head start over competitors in the RA market, says data and analytics company GlobalData.

Olumiant marks the second oral Janus kinase (JAK) inhibitor to launch for RA in the US market following the launch of Pfizer’s (NYSE: PFE) Xeljanz (tofacitinib) in November 2012. Since Olumiant will have to compete with only Xeljanz in the immediate future, GlobalData anticipates the RA drug to generate sales of $768.9 million in the USA in 2025.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK